
argenx will acquire Unnatural Products for up to $1.15B, bringing oral macrocyclic peptides and new formulation challenges to its antibody portfolio.
Click the title above to open the Pharmaceutical Technology 2018 Partnerships in Outsourcing Supplement in an interactive PDF format.
almost 9 years ago
Accelerating Early Drug Development with Translational Pharmaceuticsalmost 9 years ago
Case Study: Fast-Track Technology Transfer of a Soft-Gelatin Capsulealmost 9 years ago
QbD and API Process Development: A Marriage of Chemistry and Engineeringalmost 9 years ago
Bigger is Better in Samsung's Approach to Biomanufacturingalmost 9 years ago
Outsourcing Analytical Services in Early Drug Developmentalmost 9 years ago
Avoiding Complete Response Lettersalmost 9 years ago
A Three-Step Path Toward Combination Product Approvalalmost 9 years ago
Outsourcing: Does Focus Pay Off?almost 9 years ago
Reducing Development Timelines and Costs





